MESO watch and banter, page-47

Agreed, RMAT designation for Rex-L is an amazing milestone.

IMO it means that MSB have been working closely with the FDA, and the only reason that the FDA designated RMAT for Rex-L (CLBP) was their confidence in the potency assay linked to manufacturing and in-vivo activity based on MOA of our cells.

This is a significant confidence indicator by the FDA IMO and bodes well for our upcoming approval event for Rem-L for aGVHD.

This will mean significant revenue for MSB (see Post #:66124080)

So the traders and scaredy-cats selling atm, although dumb, will peter out, whilst at the same time provide the smart investors more opportunity to grow their holding IMO.

For anyone with half a brain, the logic follows that once Rem-L is approved, approvals for our near term blockbusters will also be a given IMO.

The results for our large phase 3, CLBP, CHF and all cause ARDS trials are incredible.

Once these absolute blockbusters are commercialised, the resultant revenue and profits will be astronomical IMO.

I am so happy I can continue to top up at what will be in the future "kick myself" price point(s).

IMO
DYOR